{
    "hands_on_practices": [
        {
            "introduction": "Understanding the kinetics of sulfation begins with the foundational Michaelis-Menten model, which describes how the rate of an enzyme-catalyzed reaction changes with substrate concentration. This first exercise allows you to apply this model to a sulfotransferase enzyme, calculating the reaction velocity for a given drug concentration . By determining the pathway's proximity to its maximum capacity, you will gain insight into the crucial concept of metabolic saturation.",
            "id": "4594120",
            "problem": "A phenolic drug is primarily cleared in the liver by a cytosolic phenol sulfotransferase (SULT1A1). Under experimental conditions, the co-substrate 3'-phosphoadenosine-5'-phosphosulfate (PAPS) is held at a saturating level, and there is no detectable product inhibition or substrate depletion. Assume single-substrate, steady-state, saturable enzyme kinetics apply. In human liver cytosol at $37\\ ^{\\circ}\\text{C}$, the enzyme exhibits a maximum velocity $V_{\\max}$ of $120\\ \\text{nmol}\\ \\text{min}^{-1}\\ \\text{mg}^{-1}$ cytosolic protein and a Michaelis constant $K_{m}$ of $8.0\\ \\mu\\text{M}$ for this substrate. Following an intravenous infusion, the measured unbound hepatic cytosolic substrate concentration is $[S] = 24.0\\ \\mu\\text{M}$.\n\nUsing only fundamental principles of single-enzyme, single-substrate steady-state kinetics, determine the instantaneous sulfation rate and the fractional activity relative to $V_{\\max}$. For the purpose of decision-making in a dose-escalation study, define a “near-saturation index” as the dimensionless ratio $\\sigma = v/V_{\\max}$, where $v$ is the reaction velocity. Report the value of $\\sigma$. Round your answer to four significant figures. Express the final answer as a dimensionless number with no units.",
            "solution": "The problem specifies a cytosolic phenol sulfotransferase (SULT1A1) operating with saturating $3'$-phosphoadenosine-$5'$-phosphosulfate (PAPS), no product inhibition, and a single substrate under steady-state conditions. The foundational base for deriving the rate law is the quasi-steady-state treatment of an enzyme $E$ binding a substrate $S$ to form the complex $ES$ that turns over to product, which yields a saturable hyperbolic dependence of velocity on substrate concentration. For a single-substrate enzyme under these conditions, the steady-state rate $v$ as a function of substrate concentration $[S]$ is given by the Michaelis–Menten relationship\n$$\nv \\;=\\; \\frac{V_{\\max}\\,[S]}{K_{m} + [S]},\n$$\nwhere $V_{\\max}$ is the maximum velocity (equal to $k_{\\text{cat}} E_{\\text{T}}$) and $K_{m}$ is the Michaelis constant.\n\nWe are given $V_{\\max} = 120\\ \\text{nmol}\\ \\text{min}^{-1}\\ \\text{mg}^{-1}$, $K_{m} = 8.0\\ \\mu\\text{M}$, and $[S] = 24.0\\ \\mu\\text{M}$. Substituting these into the rate expression,\n$$\nv \\;=\\; \\frac{\\left(120\\ \\text{nmol}\\ \\text{min}^{-1}\\ \\text{mg}^{-1}\\right)\\,\\left(24.0\\ \\mu\\text{M}\\right)}{8.0\\ \\mu\\text{M} + 24.0\\ \\mu\\text{M}}\n\\;=\\; \\frac{120 \\times 24.0}{8.0 + 24.0}\\ \\text{nmol}\\ \\text{min}^{-1}\\ \\text{mg}^{-1}.\n$$\nCompute the denominator and numerator:\n$$\n8.0 + 24.0 \\;=\\; 32.0, \\qquad 120 \\times 24.0 \\;=\\; 2880.\n$$\nThus,\n$$\nv \\;=\\; \\frac{2880}{32.0}\\ \\text{nmol}\\ \\text{min}^{-1}\\ \\text{mg}^{-1} \\;=\\; 90\\ \\text{nmol}\\ \\text{min}^{-1}\\ \\text{mg}^{-1}.\n$$\n\nThe near-saturation index is defined as the fractional activity\n$$\n\\sigma \\;=\\; \\frac{v}{V_{\\max}}.\n$$\nWe can compute $\\sigma$ either from the evaluated $v$ or directly from the hyperbolic form:\n$$\n\\sigma \\;=\\; \\frac{v}{V_{\\max}} \\;=\\; \\frac{[S]}{K_{m} + [S]} \\;=\\; \\frac{24.0}{8.0 + 24.0} \\;=\\; \\frac{24.0}{32.0} \\;=\\; 0.75.\n$$\n\nTo meet the rounding requirement of four significant figures, we report\n$$\n\\sigma \\;=\\; 0.7500.\n$$\n\nInterpretation for assessment (not part of the reported number): A commonly used operational criterion for “near saturation” is $\\sigma \\geq 0.80$ (corresponding to $[S] \\geq 4K_{m}$). Here, with $[S] = 3K_{m}$, $\\sigma = 0.75$, indicating substantial saturation but not at or above the typical near-saturation threshold.",
            "answer": "$$\\boxed{0.7500}$$"
        },
        {
            "introduction": "Sulfation does more than just metabolize a drug; it fundamentally alters its physicochemical properties, which has profound implications for its fate in the body. This practice challenges you to connect the chemical transformation—the addition of a sulfate group—to principles of acid-base chemistry and membrane transport . By analyzing the changes in ionization and lipophilicity, you will be able to predict the impact of sulfation on the drug's renal clearance.",
            "id": "4594158",
            "problem": "A phenolic drug has an experimentally measured acid dissociation constant $pK_a = 9.5$ for its phenolic hydroxyl group and an octanol–water partition coefficient expressed as $\\log P = 3.0$. After biotransformation by sulfotransferase enzymes, the resulting sulfate monoester conjugate has an acid dissociation constant $pK_a = 1.0$ for the sulfate group. At physiological plasma pH $pH = 7.4$, reason from acid–base equilibria and membrane transport principles to determine the ionization states of the parent phenol versus its sulfate conjugate, and infer the qualitative impact of sulfation on renal clearance via glomerular filtration and tubular handling. Select the single best statement.\n\nA. At $pH = 7.4$, the parent phenol is predominantly unionized and lipophilic, whereas the sulfate conjugate is predominantly a negatively charged anion; sulfation therefore increases renal clearance by reducing passive tubular reabsorption and enabling potential transport by organic anion transporters (OATs).\n\nB. At $pH = 7.4$, the parent phenol is predominantly ionized and hydrophilic, whereas the sulfate conjugate is predominantly unionized; sulfation therefore decreases renal clearance by increasing passive tubular reabsorption.\n\nC. At $pH = 7.4$, both the parent phenol and the sulfate conjugate are largely unionized; sulfation has minimal impact on renal clearance.\n\nD. Sulfation increases lipophilicity and decreases the fraction unbound, thereby reducing glomerular filtration and overall renal clearance.",
            "solution": "The user has requested a critical validation of the problem statement, followed by a detailed solution and evaluation of the given options.\n\n### Problem Validation\n\n**Step 1: Extract Givens**\n\n-   Parent phenolic drug:\n    -   Acid dissociation constant for the phenolic hydroxyl group: $pK_a = 9.5$.\n    -   Octanol–water partition coefficient: $\\log P = 3.0$.\n-   Sulfate monoester conjugate (metabolite):\n    -   Acid dissociation constant for the sulfate group: $pK_a = 1.0$.\n-   Physiological condition:\n    -   Plasma $pH = 7.4$.\n-   Question: Determine the ionization states of the parent drug and its sulfate conjugate at physiological $pH$ and infer the qualitative impact of sulfation on renal clearance.\n\n**Step 2: Validate Using Extracted Givens**\n\n-   **Scientifically Grounded**: The problem is well-grounded in the principles of acid-base chemistry, pharmacology, and pharmacokinetics. The Henderson-Hasselbalch equation governs the ionization state of weak acids. The concept of $\\log P$ as a measure of lipophilicity, and the principles of renal clearance (glomerular filtration, passive tubular reabsorption, active tubular secretion) are fundamental to the field. The provided values are realistic: phenolic $pK_a$ values are typically in the range of $8-10$, a $pK_a$ of $1.0$ is appropriate for a strong acid like a sulfate ester, physiological $pH$ is correctly stated as $7.4$, and a $\\log P$ of $3.0$ correctly represents a lipophilic compound. Sulfation is a major Phase II biotransformation pathway that increases hydrophilicity and facilitates elimination. The role of organic anion transporters (OATs) in secreting sulfate conjugates is well-established. The problem is scientifically sound.\n-   **Well-Posed**: The problem provides sufficient information ($pK_a$ values, $\\log P$, $pH$) to determine the ionization states and physicochemical properties of the parent drug and its metabolite. From these properties, a logical inference about the change in renal handling mechanisms can be made. The question asks for a qualitative determination, for which a unique and meaningful answer can be derived.\n-   **Objective**: The problem is stated using clear, precise, and objective scientific language. There are no subjective or ambiguous terms.\n\n**Step 3: Verdict and Action**\n\nThe problem statement is scientifically sound, well-posed, and objective. It is **valid**. The solution process will now proceed.\n\n### Derivation and Solution\n\nThe solution requires applying acid-base principles to determine the ionization states of the parent drug and its metabolite, and then using pharmacokinetic principles to infer the consequences for renal clearance.\n\n**1. Ionization State of the Parent Phenolic Drug**\n\nThe ionization of the phenolic hydroxyl group (a weak acid, $HA$) is described by the equilibrium:\n$$ \\text{Drug-}OH \\rightleftharpoons \\text{Drug-}O^- + H^+ $$\nThe relationship between $pH$, $pK_a$, and the ratio of the ionized form ($A^-$) to the unionized form ($HA$) is given by the Henderson-Hasselbalch equation:\n$$ pH = pK_a + \\log\\left(\\frac{[A^-]}{[HA]}\\right) $$\nGiven $pH = 7.4$ and $pK_a = 9.5$ for the parent drug:\n$$ 7.4 = 9.5 + \\log\\left(\\frac{[\\text{ionized}]}{[\\text{unionized}]}\\right) $$\n$$ \\log\\left(\\frac{[\\text{ionized}]}{[\\text{unionized}]}\\right) = 7.4 - 9.5 = -2.1 $$\n$$ \\frac{[\\text{ionized}]}{[\\text{unionized}]} = 10^{-2.1} \\approx 0.0079 $$\nSince the ratio of ionized to unionized form is approximately $1:126$, the parent drug is **predominantly unionized** at physiological $pH$. The problem also states that the parent drug has a $\\log P = 3.0$. A positive $\\log P$ value indicates that the compound is lipophilic (fat-soluble). Therefore, at $pH = 7.4$, the parent phenol is predominantly unionized and lipophilic.\n\n**2. Ionization State of the Sulfate Conjugate**\n\nThe sulfate conjugate is a sulfate monoester, which is a strong acid ($HA$). Its ionization is described by:\n$$ \\text{Drug-}O-SO_3H \\rightleftharpoons \\text{Drug-}O-SO_3^- + H^+ $$\nUsing the Henderson-Hasselbalch equation with $pH = 7.4$ and $pK_a = 1.0$:\n$$ 7.4 = 1.0 + \\log\\left(\\frac{[\\text{ionized}]}{[\\text{unionized}]}\\right) $$\n$$ \\log\\left(\\frac{[\\text{ionized}]}{[\\text{unionized}]}\\right) = 7.4 - 1.0 = 6.4 $$\n$$ \\frac{[\\text{ionized}]}{[\\text{unionized}]} = 10^{6.4} \\approx 2,500,000 $$\nThe ratio of ionized to unionized form is extremely large. The sulfate conjugate is **predominantly ionized**, existing almost exclusively as a negatively charged anion ($\\text{Drug-}O-SO_3^-$) at physiological $pH$. The addition of a charged sulfate group dramatically increases the molecule's polarity and water solubility (hydrophilicity), meaning its $\\log P$ value would be significantly lower (likely negative) than the parent drug's.\n\n**3. Impact on Renal Clearance**\n\nRenal clearance involves three processes: glomerular filtration, passive tubular reabsorption, and active tubular secretion.\n\n-   **Passive Tubular Reabsorption**: This process allows lipophilic, unionized molecules to diffuse from the renal tubule back into the bloodstream, thus reducing their net excretion. The parent drug, being predominantly unionized and lipophilic, is an ideal candidate for extensive passive reabsorption. The sulfate conjugate, being highly ionized and hydrophilic, cannot easily cross the tubular membrane and will undergo very little, if any, passive reabsorption. Therefore, sulfation **reduces passive tubular reabsorption**.\n\n-   **Active Tubular Secretion**: The renal tubules contain specific transporters that actively pump substances into the urine. Organic Anion Transporters (OATs) are responsible for the secretion of a wide variety of organic anions. The sulfate conjugate is an organic anion and is a typical substrate for OATs. Therefore, sulfation **enables active tubular secretion**.\n\n-   **Glomerular Filtration**: Filtration rate is proportional to the fraction of drug unbound to plasma proteins ($f_u$). Highly lipophilic drugs often bind extensively to plasma proteins like albumin. The conversion to a highly polar, hydrophilic metabolite generally reduces protein binding, thereby increasing $f_u$ and enhancing clearance by filtration.\n\n**Conclusion**: Sulfation transforms a lipophilic drug (subject to extensive reabsorption) into a hydrophilic anion that is trapped in the renal tubule (minimal reabsorption) and is also a substrate for active secretion by OATs. All these factors combine to dramatically **increase** the overall renal clearance of the drug.\n\n### Option-by-Option Analysis\n\n**A. At $pH = 7.4$, the parent phenol is predominantly unionized and lipophilic, whereas the sulfate conjugate is predominantly a negatively charged anion; sulfation therefore increases renal clearance by reducing passive tubular reabsorption and enabling potential transport by organic anion transporters (OATs).**\n-   The assessment of the parent phenol (predominantly unionized, lipophilic) is **correct**.\n-   The assessment of the sulfate conjugate (predominantly a negatively charged anion) is **correct**.\n-   The inferred impact on renal clearance (increased) and the stated mechanisms (reducing passive reabsorption, enabling OAT transport) are both **correct**.\n-   This statement accurately integrates all the derived conclusions. The verdict is **Correct**.\n\n**B. At $pH = 7.4$, the parent phenol is predominantly ionized and hydrophilic, whereas the sulfate conjugate is predominantly unionized; sulfation therefore decreases renal clearance by increasing passive tubular reabsorption.**\n-   The assessment of the parent phenol (predominantly ionized) is **incorrect**. As shown, since a weak acid's $pH < pK_a$, it is predominantly unionized. The $\\log P=3.0$ indicates it is lipophilic, not hydrophilic.\n-   The assessment of the sulfate conjugate (predominantly unionized) is **incorrect**. As shown, since a strong acid's $pH > pK_a$, it is predominantly ionized.\n-   The entire premise of this option is factually wrong. The verdict is **Incorrect**.\n\n**C. At $pH = 7.4$, both the parent phenol and the sulfate conjugate are largely unionized; sulfation has minimal impact on renal clearance.**\n-   The assessment of the parent phenol (largely unionized) is **correct**.\n-   The assessment of the sulfate conjugate (largely unionized) is **incorrect**.\n-   The conclusion that sulfation has minimal impact on clearance is **incorrect**; the impact is substantial.\n-   The verdict is **Incorrect**.\n\n**D. Sulfation increases lipophilicity and decreases the fraction unbound, thereby reducing glomerular filtration and overall renal clearance.**\n-   The claim that sulfation increases lipophilicity is **incorrect**. Sulfation adds a highly polar, charged group, which dramatically *decreases* lipophilicity (increases hydrophilicity).\n-   The claim that sulfation decreases the fraction unbound (i.e., increases protein binding) is generally **incorrect**. The increased polarity usually *decreases* protein binding, increasing the fraction unbound.\n-   The conclusion that sulfation reduces renal clearance is **incorrect**.\n-   Every part of this statement is the opposite of the established principles. The verdict is **Incorrect**.",
            "answer": "$$\\boxed{A}$$"
        },
        {
            "introduction": "A central goal of clinical pharmacology is to predict how a drug will behave in a patient based on laboratory data. This final practice guides you through an in vitro-to-in vivo extrapolation (IVIVE), where you will scale up enzyme kinetic parameters measured in the lab to predict the drug's hepatic clearance at the whole-organ level . Mastering this quantitative approach is essential for forecasting drug disposition and informing dosing strategies.",
            "id": "4594097",
            "problem": "A small-molecule drug undergoes hepatic sulfation primarily via cytosolic Sulfotransferases (SULTs), which utilize the cofactor $3'$-phosphoadenosine-$5'$-phosphosulfate (PAPS). In vitro enzyme kinetic characterization was performed in human liver cytosol under saturating PAPS and yielded a maximum rate $V_{\\max} = 240\\ \\text{pmol}\\ \\text{min}^{-1}\\ \\text{mg}^{-1}$ cytosolic protein and a Michaelis constant $K_m = 40\\ \\mu\\text{M}$ for the drug substrate. The liver cytosolic protein content is $50\\ \\text{mg}\\ \\text{g}^{-1}$ liver, and the average liver mass is $22\\ \\text{g}\\ \\text{kg}^{-1}$ body weight. Hepatic blood flow is $1.35\\ \\text{L}\\ \\text{h}^{-1}\\ \\text{kg}^{-1}$. The fraction unbound in whole blood is $f_{u,b} = 0.35$. Therapeutic free drug concentrations in blood are maintained well below the in vitro $K_m$ for sulfation.\n\nUsing first principles of enzyme kinetics and mass balance for a well-stirred liver, compute the hepatic clearance of the drug. Express your final answer in $\\text{L}\\ \\text{h}^{-1}\\ \\text{kg}^{-1}$ and round to three significant figures.",
            "solution": "The problem requires the computation of hepatic clearance ($CL_H$) using the well-stirred liver model. The solution proceeds by first validating the problem statement and then performing a step-by-step calculation based on first principles of enzyme kinetics and physiology-based pharmacokinetic modeling.\n\n### Step 1: Extract Givens\n- Maximum rate of sulfation, $V_{\\max} = 240\\ \\text{pmol}\\ \\text{min}^{-1}\\ \\text{mg}^{-1}$ cytosolic protein.\n- Michaelis constant for the drug, $K_m = 40\\ \\mu\\text{M}$.\n- Liver cytosolic protein content = $50\\ \\text{mg}\\ \\text{g}^{-1}$ liver.\n- Average liver mass = $22\\ \\text{g}\\ \\text{kg}^{-1}$ body weight.\n- Hepatic blood flow, $Q_H = 1.35\\ \\text{L}\\ \\text{h}^{-1}\\ \\text{kg}^{-1}$.\n- Fraction unbound in whole blood, $f_{u,b} = 0.35$.\n- Condition: Therapeutic free drug concentrations in blood are well below $K_m$.\n- Model: Well-stirred liver.\n\n### Step 2: Validate Using Extracted Givens\n- **Scientifically Grounded**: The problem is based on established principles of Michaelis-Menten enzyme kinetics and the well-stirred model of hepatic clearance, which are standard in clinical pharmacology. The values provided for physiological and biochemical parameters are realistic.\n- **Well-Posed**: The problem is self-contained and provides all necessary data to calculate the hepatic clearance. The condition that free drug concentration is much less than $K_m$ allows for a simplification that makes the problem uniquely solvable.\n- **Objective**: The problem is stated using precise, objective scientific language.\n\nThe problem is valid as it is scientifically sound, well-posed, and objective. It does not violate any of the specified invalidity criteria. We can proceed with the solution.\n\n### Step 3: Derivation and Calculation\nThe hepatic clearance ($CL_H$), according to the well-stirred liver model, is given by:\n$$CL_H = \\frac{Q_H \\cdot f_{u,b} \\cdot CL_{int}}{Q_H + f_{u,b} \\cdot CL_{int}}$$\nwhere $Q_H$ is the hepatic blood flow, $f_{u,b}$ is the fraction of drug unbound in blood, and $CL_{int}$ is the intrinsic clearance. The values for $Q_H$ and $f_{u,b}$ are given, but $CL_{int}$ must be calculated by scaling up the in vitro kinetic data.\n\nThe intrinsic clearance ($CL_{int}$) represents the maximal metabolic capacity of the liver for the drug, independent of blood flow limitations. The rate of metabolism ($v$) is described by the Michaelis-Menten equation:\n$$v = \\frac{V_{\\max} \\cdot C_u}{K_m + C_u}$$\nwhere $C_u$ is the unbound substrate (drug) concentration.\n\nThe problem states that therapeutic free drug concentrations are well below the $K_m$ ($C_u \\ll K_m$). Under this condition, the denominator simplifies to $K_m$, and the kinetics become first-order:\n$$v \\approx \\frac{V_{\\max}}{K_m} \\cdot C_u$$\nThe term $\\frac{V_{\\max}}{K_m}$ represents the intrinsic clearance based on unbound drug concentration, per unit of protein. Let us denote this in vitro intrinsic clearance as $CL_{int, \\text{in vitro}}$.\n\nFirst, we calculate $CL_{int, \\text{in vitro}}$. We must ensure consistent units.\nThe given parameters are:\n$$V_{\\max} = 240\\ \\text{pmol}\\ \\text{min}^{-1}\\ \\text{mg}^{-1}$$\n$$K_m = 40\\ \\mu\\text{M} = 40\\ \\mu\\text{mol}\\ \\text{L}^{-1} = 40 \\times 10^6\\ \\text{pmol}\\ \\text{L}^{-1}$$\nNow, we can compute $CL_{int, \\text{in vitro}}$:\n$$CL_{int, \\text{in vitro}} = \\frac{V_{\\max}}{K_m} = \\frac{240\\ \\text{pmol}\\ \\text{min}^{-1}\\ \\text{mg}^{-1}}{40 \\times 10^6\\ \\text{pmol}\\ \\text{L}^{-1}} = 6.0 \\times 10^{-6}\\ \\text{L}\\ \\text{min}^{-1}\\ \\text{mg}^{-1}$$\nThe target units for clearance are $\\text{L}\\ \\text{h}^{-1}\\ \\text{kg}^{-1}$. We convert the time unit from minutes to hours:\n$$CL_{int, \\text{in vitro}} = 6.0 \\times 10^{-6}\\ \\frac{\\text{L}}{\\text{min} \\cdot \\text{mg}} \\times 60\\ \\frac{\\text{min}}{\\text{h}} = 3.6 \\times 10^{-4}\\ \\text{L}\\ \\text{h}^{-1}\\ \\text{mg}^{-1}$$\n\nNext, we must scale this in vitro value to the whole liver, normalized by body weight. We calculate the total mass of cytosolic protein per kilogram of body weight using the given scaling factors:\n- Liver cytosolic protein content: $S_p = 50\\ \\text{mg protein}\\ \\text{g}^{-1}\\ \\text{liver}$\n- Liver mass per body weight: $M_L = 22\\ \\text{g liver}\\ \\text{kg}^{-1}\\ \\text{body weight}$\n\nThe total scaling factor (SF), representing milligrams of protein per kilogram of body weight, is:\n$$SF = S_p \\times M_L = \\left(50\\ \\frac{\\text{mg}}{\\text{g}}\\right) \\times \\left(22\\ \\frac{\\text{g}}{\\text{kg}}\\right) = 1100\\ \\text{mg protein}\\ \\text{kg}^{-1}\\ \\text{body weight}$$\n\nNow, we can calculate the total intrinsic clearance for the liver, normalized per kilogram of body weight ($CL_{int}$):\n$$CL_{int} = CL_{int, \\text{in vitro}} \\times SF = (3.6 \\times 10^{-4}\\ \\text{L}\\ \\text{h}^{-1}\\ \\text{mg}^{-1}) \\times (1100\\ \\text{mg}\\ \\text{kg}^{-1})$$\n$$CL_{int} = 0.396\\ \\text{L}\\ \\text{h}^{-1}\\ \\text{kg}^{-1}$$\n\nWith $CL_{int}$ determined, we can now calculate the hepatic clearance $CL_H$ using the well-stirred model equation. First, we compute the term $f_{u,b} \\cdot CL_{int}$:\n$$f_{u,b} \\cdot CL_{int} = 0.35 \\times 0.396\\ \\text{L}\\ \\text{h}^{-1}\\ \\text{kg}^{-1} = 0.1386\\ \\text{L}\\ \\text{h}^{-1}\\ \\text{kg}^{-1}$$\n\nFinally, substitute all values into the equation for $CL_H$.\nThe given hepatic blood flow is $Q_H = 1.35\\ \\text{L}\\ \\text{h}^{-1}\\ \\text{kg}^{-1}$.\n$$CL_H = \\frac{Q_H \\cdot (f_{u,b} \\cdot CL_{int})}{Q_H + (f_{u,b} \\cdot CL_{int})} = \\frac{1.35 \\cdot 0.1386}{1.35 + 0.1386}\\ \\text{L}\\ \\text{h}^{-1}\\ \\text{kg}^{-1}$$\n$$CL_H = \\frac{0.18711}{1.4886}\\ \\text{L}\\ \\text{h}^{-1}\\ \\text{kg}^{-1} \\approx 0.12569\\ \\text{L}\\ \\text{h}^{-1}\\ \\text{kg}^{-1}$$\n\nThe problem requires the answer to be rounded to three significant figures.\n$$CL_H \\approx 0.126\\ \\text{L}\\ \\text{h}^{-1}\\ \\text{kg}^{-1}$$",
            "answer": "$$\\boxed{0.126}$$"
        }
    ]
}